GMGaëlle Guiewi Makafe

Gaëlle Guiewi Makafe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gaëlle Guiewi Makafe has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Engineered probiotics target granulomas to treat mycobacterial infection

    by Yu-Yu Chen, Tetsuhiro Harimoto, Gaëlle Guiewi Makafe, Courtney Coker, Hannah Kim, Jongwon Im, Yuanqi Jing, Hayoung Jin, Xiaoyu Hu, Sharicka Zutshi, et al.

    Granulomas are a pathological niche for mycobacteria that remain difficult to access with conventional therapies. Here we show that probiotic Escherichia coli Nissle 1917 (EcN) infiltrates and colonizes granulomas and can be engineered as a delivery system that senses the local microenvironment and releases antimycobacterial payloads. Specifically, we leveraged the hypoxic microenvironment of necrotic granulomas to restrict bacterial growth, and developed a dual-mode lysis circuit combining intracellular and extracellular killing for sustained payload release with limited evolutionary escape. We further engineered EcN to express a mycobacteriophage-derived enzyme, generating a strain that suppressed drug-sensitive and drug-resistant mycobacteria in vitro and potentiated conventional antibiotic activity. Engineered probiotics also reduced mycobacterial burden in vivo, and in a murine model of rifampicin-resistant infection, combination treatment with pretomanid achieved greater bacterial reduction than either monotherapy. Together, these results establish a synthetic biology framework for targeting granulomatous infections with programmable living microbes.

  • Top Cited Papers

    An ultrasensitive and specific point-of-care CRISPR/Cas12 based lateral flow biosensor for the rapid detection of nucleic acids

    by Omar Mukama, Jinghua Wu, Zhiyuan Li, Qiongxin Liang, Zhijian Yi, Xuewen Lu, Yujie Liu, Yumei Liu, Muzammal Hussain, Gaelle Guiewi Makafe, et al.


  • Quinoline Derivatives Kill Mycobacterium tuberculosis by Activating Glutamate Kinase

    by Gaelle G. Makafe, Muzammal Hussain, Goverdhan Surineni, Yaoju Tan, Nai-Kei Wong, Mugweru Julius, Lanying Liu, Chiwala Gift, Huofeng Jiang, Yunxiang Tang, et al.


  • Open Access

    The compound TB47 is highly bactericidal against Mycobacterium ulcerans in a Buruli ulcer mouse model

    by Yang Liu, Yamin Gao, Jianxiong Liu, Yaoju Tan, Zhiyong Liu, Chiranjibi Chhotaray, Huofeng Jiang, Zhili Lu, Gift Chiwala, Shuai Wang, et al.

    Buruli ulcer (BU) is an emerging infectious disease that causes disfiguring skin ulcers. The causative agent, Mycobacterium ulcerans, secretes toxin called mycolactone that triggers inflammation and immunopathology. Existing treatments are lengthy and consist of drugs developed for tuberculosis. Here, we report that a pyrazolo[1,5-a]pyridine-3-carboxamide, TB47, is highly bactericidal against M. ulcerans both in vitro and in vivo. In the validated mouse model of BU, TB47 alone reduces M. ulcerans burden in mouse footpads by more than 2.5 log10 CFU compared to the standard BU treatment regimen recommended by the WHO. We show that mutations of ubiquinol-cytochrome C reductase cytochrome subunit B confer resistance to TB47 and the dissimilarity of CydABs from different mycobacteria may account for their differences in susceptibility to TB47. TB47 is highly potent against M. ulcerans and possesses desirable pharmacological attributes and low toxicity that warrant further assessment of this agent for treatment of BU.


  • Open Access

    Mutation EthAW21R confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv

    by Julius Mugweru, Jianxiong Liu, Gaelle Makafe, Gift Chiwala, Bangxing Wang, Changwei Wang, Xinjie Li, Yaoju Tan, Wing Wai Yew, Shouyong Tan, et al.

    Ethionamide (ETA) and prothionamide (PRO) are interchangeably used in tuberculosis (TB) chemotherapy regimens. Subtle discrepancies between biochemical and genetic information on the modes of sensitivity and resistance of isoniazid (INH) and ETA warrants further studies. We report a new mutation - EthA(W21R) - in Mycobacterium bovis Bacillus Calmette-Guerin that corresponds with co-resistance to both PRO and ETA, which to the best of our knowledge has not been reported before. Our findings suggest that mutation EthA(W21R) could be used as a marker site for testing PRO and ETA cross-resistance.

  • Open Access

    A Cassette Containing Thiostrepton, Gentamicin Resistance Genes, and dif sequences Is Effective in Construction of Recombinant Mycobacteria

    by Julius Mugweru, Gaelle Makafe, Yuanyuan Cao, Yang Zhang, Bangxing Wang, Shaobo Huang, Moses Njire, Chiranjibi Chhotaray, Yaoju Tan, Xinjie Li, et al.

    The genetic manipulation of Mycobacterium tuberculosis genome is limited by the availability of selection markers. Spontaneous resistance mutation rate of M. tuberculosis to the widely used kanamycin is relatively high which often leads to some false positive transformants. Due to the few available markers, we have created a cassette containing thiostrepton resistance gene (tsr) for selection in M. tuberculosis and M. bovis BCG, and gentamicin resistance gene (aacC1) for Escherichia coli and M. smegmatis mc2155, flanked with dif sequences recognized by the Xer system of mycobacteria. This cassette adds to the limited available selection markers for mycobacteria.


  • Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis

    by Gaëlle Guiewi Makafe, Yuanyuan Cao, Yaoju Tan, Mugweru Julius, Zhiyong Liu, Changwei Wang, Moses M. Njire, Xingshan Cai, Tianzhou Liu, Bangxing Wang, et al.

    We expressed the wild-type rplC and mutated rplC (Cys154Arg) genes, respectively, in Mycobacterium tuberculosis H37Ra and H37Rv in an attempt to delineate the role of rplC (Cys154Arg) regarding oxazolidinone resistance. An increase of the MICs of linezolid (LZD) and sutezolid (PNU-100480, PNU) against the recombinant mycobacteria with overexpressed rplC mutation (Cys154Arg) was found, suggesting the rplC gene is a determinant of bacillary susceptibilities to LZD and PNU.


  • Open Access

    Sequence analysis for detection of drug resistance in Mycobacterium tuberculosis complex isolates from the Central Region of Cameroon

    by Emmanuel Mouafo Tekwu, Larissa Kamgue Sidze, Jean-Paul Assam Assam, Jean-Claude Tedom, Serges Tchatchouang, Gaëlle Guiewi Makafe, Anne-Laure Tchokote Wetewale, Christopher Kuaban, Sara Eyangoh, Francine Ntoumi, et al.

    The potential of genetic testing to rapidly diagnose drug resistance has lead to the development of new diagnostic assays. However, prior to implementation in a given setting, the association of specific mutations with specific drug resistance phenotypes should be evaluated. The purpose of this study was to evaluate molecular markers in predicting drug resistance in the Central Region of Cameroon. From April 2010 and March 2011, 725 smear positive pulmonary tuberculosis patients were enrolled and all positive cultures were tested for drug susceptibility. A total of 63 drug resistant and 100 drug sensitive Mycobacterium tuberculosis complex clinical isolates were screened for genetic mutations in katG, inhA, ahpC, rpoB, rpsL, rrs, gidB and embCAB loci using DNA sequencing. Of the 44 isoniazid resistant (INHR) isolates (24 high level, 1 μg/ml and 20 low level, 0.2 μg/ml), 73% (32/44) carried the katG315 and/or the -15 inhA promoter mutations. Of the 24 high level INHR, 17 (70.8%) harbored katG315 mutation, 1 a point mutation (-15C → T) in the inhA promoter and 6 were (25.0%) wild types. Thus, for INHR high level detection, katG315 mutation had a specificity and a sensitivity of 100% and 70.8% respectively. Of the 20 low level INHR, 10 (50.0%) had a -15C → T mutation in the inhA promoter region, and 1 (2.2%) a -32G → A mutation in the ahpC promoter region. All of the 7 rifampicin resistant (RIFR) isolates carried mutations in the rpoB gene (at codons Ser531Leu (71.4%), His526Asp (14.3%), and Asp516Val (14.3%)). Of the 27 streptomycin resistant (SMR) isolates, 7 carried mutations at the rpsL and the gidB genes. 1 of the 2 ethambutol resistant (EMB R) isolates displayed a mutation in embB gene. This study provided the first molecular investigation assessing the correlation of phenotypic to genotypic characteristics on MTB isolates from the Central Region of Cameroon using DNA sequencing. Mutations on rpoB, katG315 and -15 point mutations in inhA promoter loci could be used as markers for RIF and INH -resistance detection respectively.